We are pleased to announce that our patent covering Nasodine ® Nasal Spray1 as a treatment and preventative for the common cold has been granted in Singapore.
This brings the number of countries where Firebrick’s core patent has been granted to 27, including:
The patent is still pending in Canada and Japan. The pending application in China has now been withdrawn, following a recent assessment of the likelihood and costs of gaining any commercially-useful protection in that market.
The core Nasodine patent, which expires in most countries in 2035, is titled: “Treatment and prevention of the common cold using povidone-iodine,” and protects the intranasal use of povidone-iodine (in any form) for the treatment or prevention of the common cold.
Granted claims include treating and preventing colds, reducing the viral load of common cold viruses, prevention of secondary complications of colds, and reducing the risk of serious complications in at-risk populations.
1Nasodine is not yet available for sale in Australia or elsewhere.